Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine

Clinical Infectious Diseases

Volumn 40, Issue 9, 2005, Pages 1271-1281

  Bernstein, David I ^a,j   Aoki, Fred Y ^d   Tyring, Stephen K ^b   Stanberry, Lawrence R ^c   St Pierre, Claude ^e   Shafran, Stephen D ^f   Leroux Roels, Geert ^g   Van Herck, Koen ^h   Bollaerts, Anne ⁱ   Dubin, Gary ⁱ  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Novabyss Inc   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g GHENT UNIVERSITY   (Belgium)

^h UNIVERSITY OF ANTWERP   (Belgium)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^j CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; PHOSPHORYL LIPID A; PLACEBO; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GENITAL HERPES; HEADACHE; HERPES SIMPLEX VIRUS 2; HUMAN; HYPERVENTILATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TINGLING; SYNCOPE; TASTE DISORDER; THROAT DISEASE; TONGUE TINGLING; VACCINATION; VIRUS IMMUNITY; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HUMANS; MALE; MIDDLE AGED; VIRAL ENVELOPE PROTEINS;

EID: 20244377971     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429240     Document Type: Article

References (14)

1. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
2. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52.
3. Wald A, Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis 2003; 187:1509-12.
4. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1513-21.
5. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-61.
6. Smith JW, Fletcher WB, Wherry PJ. Reactions to injected influenza vaccine. Dev Biol Stand 1975; 28:377-88.
7. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med 1996; 156:1546-50.
8. Jackson LA, Austin G, Chen RT, et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001; 19:4703-9.
9. Mitchell JR, Whitney FW. The effect of injection speed on the perception of intramuscular injection pain. A clinical update. AAOHN J 2001; 49:286-92.
10. Wasserman GM, Grabenstein JD, Pittman PR, et al. Analysis of adverse events after anthrax immunization in US Army medical personnel. J Occup Environ Med 2003; 45:222-33.
11. Pittman PR. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 2002; 20(Suppl 3):S48-50.
12. Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. Anthrax vaccine: short-term safety experience in humans. Vaccine 2001; 20:972-8.
13. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994; 343:1460-3.
14. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176:1129-34.